Browse News
Filter News
Found 420 articles
-
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
3/27/2024
SeaStar Medical Holding Corporation announces that it will restate its financial statements for the fiscal year ended December 31, 2022 and for the interim periods ended March 31, 2023, June 30, 2023 and September 30, 2023.
-
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
3/22/2024
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and twelve months ended December 31, 2023 financial results.
-
ANEW MEDICAL Announces Key Patent Issued in China to Protect Klotho Protein and Gene Delivery Systems
3/4/2024
ANEW MEDICAL, INC. announced that is has been granted and issued a patent in China, number CN 117126829 A for the use of ANEW's Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases.
-
BioHarvest Sciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
2/15/2024
BioHarvest Sciences Inc., (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company"), a biotechnology company pioneering botanical synthesis, has engaged investor relations specialists
-
Mirion Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Guidance
2/13/2024
Mirion ("we" or the "company") (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the fourth quarter and full year ended December 31, 2023.
-
Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024
1/23/2024
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 25, 2024, the Company will implement a 1-for-30 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 17, 2024.
-
The blank check company Thursday filed with the SEC for the initial public offering. While a specific business for Helix Acquisition Corp. II has not yet been identified, the fund will target biotech.
-
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
11/29/2023
Ocean Biomedical, Inc., announced that on November 22, 2023, it received a notice from The Nasdaq Stock Market LLC stating that because the Company has not yet filed its quarterly report on Form 10-Q for the period ended September 30, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250, which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission.
-
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023
11/13/2023
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and nine months ended September 30, 2023 financial results.
-
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
10/24/2023
Citius Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement, dated October 23, 2023, for a proposed merger of TenX and Citius Pharma's wholly owned oncology subsidiary that will continue as a public company listed on the Nasdaq exchange.
-
Starton Therapeutics Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma
10/4/2023
Starton Therapeutics Inc. announced the dosing of the first patient in the STAR-LLD Phase 1b clinical trial, which will assess the safety, efficacy and pharmacokinetics of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) for the treatment of multiple myeloma (MM).
-
Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with a Key Financing Partner
10/3/2023
Ocean Biomedical, Inc. announced that the company and Polar Multi-Strategy Master Fund, a significant long-time financing partner of Ocean Biomedical, agreed to amend the agreement between the parties related to the Forward Shares Purchase Agreement entered into in February 2023.
-
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
10/2/2023
Revelation Biosciences Inc. today announced the appointment of Lakhmir Chawla M.D. to the Company’s Board of Directors (Board).
-
Enzolytics Announces the Signing of the Business Combination Agreement with Sagaliam Acquisition Corp (SAGA)
9/18/2023
Enzolytics, Inc. (OTC PINK:ENZC) ( https://enzolytics.com ). Enzolytics, Inc. announces today that it has executed the binding business combination agreement for the sale of Biogenysis, Inc.and Virogentics Inc. the operating subsidiaries of Enzolytics Inc., to Sagaliam Acquisition Corp (NASDAQ: SAGA) in a transaction valued at $450,000,000.
-
Starton Therapeutics Announces the Opening of the First Clinical Site for STAR-LLD Lenalidomide Phase 1b Trial in Multiple Myeloma
9/13/2023
Starton Therapeutics Inc. (“Starton” or “the Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced Gabrail Cancer Center (GCC) in Canton, Ohio as the first site activated in the STAR-LLD Phase 1b clinical trial.
-
Warning signs that preceded the current economic squeeze in the biopharma sector were not heeded by investors seeking rapid profits. Now, biotechs interested in making the leap to the public markets must get creative.
-
Citryll Announces Appointments of Eduardo Bravo as CEO and Tim Schenk as CBO
8/29/2023
Citryll announced the appointment of Eduardo Bravo as Chief Executive Officer.
-
PureTech Health plc – 2023 Half-Year Report
8/29/2023
PureTech Health plc announces its half-yearly results for the six months ended June 30, 2023.
-
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
8/28/2023
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, announced the appointment of Jeff Caravella as Chief Financial Officer.
-
Biogenysis’ International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.
8/24/2023
Biogenysis, Inc. (OTC PINK:ENZC) (or the "Company"). Biogenysis, a subsidiary of Enzolytics, Inc., announces the progress of its Patent Cooperation Treaty (PCT) application covering its inventions relating to Anti-SARS-CoV-2 Monoclonal Antibodies.